This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Bausch & Lomb U.K Limited

Bausch & Lomb House, 106 London Road, Kingston-upon-Thames, Surrey, KT2 6TN, UK
Telephone: +44 (0)208 781 2900
Fax: +44 (0)208 781 2901
Medical Information Direct Line: +44(0)1748 828849 or 08 1871 9318
Medical Information e-mail:
Customer Care direct line: +44 (0)208781 2991

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 16/07/2012
SPC Minims Chloramphenicol 0.5%, Eye drops solution

Go to top of the page
1. Name of the medicinal product

Minims Chloramphenicol 0.5%

Go to top of the page
2. Qualitative and quantitative composition

Clear, colourless, sterile eye drops containing Chloramphenicol PhEur 0.5% w/v.

Go to top of the page
3. Pharmaceutical form

Sterile single use eye drop.

Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Chloramphenicol is a broad spectrum bacteriostatic antibiotic. It is active against a wide variety of gram-negative and gram-positive organisms as well as rickettsiae and spirochaetes. It is indicated for use as a topical antibacterial in the treatment of superficial ocular infections.

Go to top of the page
4.2 Posology and method of administration

Adults (including the Elderly) and Children

One to two drops applied topically to each affected eye up to six times daily or more frequently if required. (Severe infections may require one to two drops every fifteen to twenty minutes initially, reducing the frequency of instillation gradually as the infection is controlled).

Go to top of the page
4.3 Contraindications

Hypersensitivity to chloramphenicol or any component of the preparation.

Go to top of the page
4.4 Special warnings and precautions for use

In severe infections topical use of chloramphenicol should be supplemented with appropriate systemic treatment.

Aplastic anaemia has, rarely, followed topical use of chloramphenicol eye drops and, whilst this hazard is an uncommon one, it should be borne in mind when the benefits of the use of chloramphenicol are assessed.

Prolonged use should be avoided as it may increase the likelihood of sensitisation and the emergence of resistant organisms.

Contact lenses should be removed during the period of treatment.

Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following the instillation of the drops. (This blocks the passage of the drops via the naso lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa. It is especially advisable in children.)

Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Chymotrypsin will be inhibited if given simultaneously with chloramphenicol.

Go to top of the page
4.6 Pregnancy and lactation

Safety for use in pregnancy and lactation has not been established, therefore, use only when considered essential by the physician.

Go to top of the page
4.7 Effects on ability to drive and use machines

May cause transient blurring of vision on installation. Warn patients not to drive or operate hazardous machinery unless vision is clear.

Go to top of the page
4.8 Undesirable effects


Sensitivity reactions such as transient irritation, burning, stinging, itching and dermatitis, may occur.


Rarely, cases of major adverse haematological events (bone marrow depression, aplastic anaemia and death) have been reported following ocular use of chloramphenicol.

Go to top of the page
4.9 Overdose

Not applicable.

Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Chloramphenicol is an antibiotic which is mainly bacteriostatic in action, but exerts a bactericidal effect against some strains of gram-positive cocci and against Haemophilus influenzae and Neisseria. It has a broad spectrum of action against both gram-positive and gram-negative bacteria, rickettsiae and chlamydia.

Go to top of the page
5.2 Pharmacokinetic properties

Chloramphenicol is rapidly absorbed after oral administration. In the liver, chloramphenicol is inactivated by conjugation with glucuronic acid or by reduction to inactive aryl amines. Excretion is mainly renal, though some bile excretion occurs following oral administration.

Go to top of the page
5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients


Boric acid

Purified water

Go to top of the page
6.2 Incompatibilities

None known.

Go to top of the page
6.3 Shelf life

30 months.

Go to top of the page
6.4 Special precautions for storage

Store between 2° and 8°C. Do not freeze. Protect from light.

If necessary, the product may be stored at temperatures not exceeding 25°C for up to 1 month only.

Go to top of the page
6.5 Nature and contents of container

A sealed conical shaped polypropylene container fitted with a twist and pull off cap. Each Minims Chloramphenicol unit is overwrapped in an individual polyethylene sachet. 20 units each containing 0.5ml are packed into a suitable carton.

Go to top of the page
6.6 Special precautions for disposal and other handling

Each Minims unit should be discarded after a single use.

If the product is to be stored unrefrigerated at temperatures not exceeding 25°C, prior to supply of the product by the pharmacy the adhesive label provided in the carton should be completed and affixed over the bar code, by a pharmacist. An expiry date one month from the supply date, plus the pharmacist's initials should be written in the spaces provided on this label.

Go to top of the page
7. Marketing authorisation holder

Chauvin Pharmaceuticals Ltd

106 London Road




Go to top of the page
8. Marketing authorisation number(s)

PL 0033/0055R

Go to top of the page
9. Date of first authorisation/renewal of the authorisation

Date of Grant:


Date of Renewal:


Go to top of the page
10. Date of revision of the text

November 2002

Go to top of the page
11. Legal category


More information about this product

Link to this document from your website:

Active Ingredients/Generics